Skip to main content

Table 2 Treatment-emergent adverse events (TEAEs) reported in ≥5% patients by organ system

From: Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

System Organ Class Samalizumab Treatment Group
50 mg/m2 N = 4 100 mg/m2 N = 5 200 mg/m2 N = 3 300 mg/m  N = 3 400 mg/m2 N = 3 500 mg/m2 N = 7 600 mg/m2 N = 1 Overall N = 26
General Disorders and Administration Sites         11 (42)
 Fatigue 1 (25) – 1 (33) 3 (100) – 1 (14) –  
 Peripheral coldness 1 (25) – – – – – –  
 Pyrexia – – – – – 1 (14) –  
 Chills – – – – – 1 (14) –  
 Edema – – – 2 (67) – – –  
Skin and Subcutaneous Tissue         9 (35)
 Erythema – – – 1 (33) – – –  
 Night sweats – – – – – 1 (14) –  
 Pruritus 1 (25) 1 (20) – – – – –  
 Rash 1 (25) 1 (20) 1 (33) 1 (33) – – –  
 Urticaria 1 (25) – – – – – –  
Gastrointestinal         5 (19)
 Abdominal distension – – – 1 (33) – – –  
 Abdominal Pain – – – 2 (67) – – –  
 Diarrhea 1 (25) 1 (20) – – – – –  
Infections and Infestations         4 (15)
 Upper Respiratory Tract Infection – 1 (20) – – 1 (33) 1 (14) –  
 Abscess – – – 1 (33) – – –  
Musculoskeletal and Connective Tissue         4 (15)
 Arthralgia – – – 1 (33) – – –  
 Muscular weakness 1 (25) – – – – – –  
 Myalgia 1 (25) – – – – – –  
 Stiffness – 1 (20) – – – – –  
Nervous System         3 (12)
 Dizziness – – – 1 (33) – – –  
 Headache – – – – – 1 (14) –  
 Paraesthesia – – – 1 (33) – – –  
Blood and Lymphatic System         7 (27)
 Anemia – – – 1 (33) 1 (33) – –  
 Neutropenia 2 (50) – – 1 (33) 1 (33) – –  
 Thrombocytopenia – – – – 1 (33) – –  
Eye         6 (23)
 Eye pain 1 (25) – – – – 1 (14) –  
 Night blindness 1 (25) – – – – – –  
 Photophobia 1 (25) – – – – 1 (14) –  
 Reduced visual acuity 1 (25) – – – – – –  
Laboratory –   –   – – – 2 (8)
 Increased blood viscosity   –   1 (33)   –   
 Decreased platelets   1 (20)     –   
Respiratory, Thoracic and Mediastinal         4 (15)
 Cough – – – – – 1 (14) –  
 Dyspnea – – – 1 (33) – 1 (14) –  
 Pulmonary edema – – – – – 1 (14) –  
  1. Values in parentheses are the percentage of patients
  2. Only one occurrence per patient counted for each category
  3. “-” indicates zero
Back to article page